Chronic Rhinosinusitis with Nasal Polyps Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | AstraZeneca, Amgen, Keymed Biosciences, GlaxoSmithKline

Posted on
by

Chronic Rhinosinusitis with Nasal Polyps Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | AstraZeneca, Amgen, Keymed Biosciences, GlaxoSmithKline
The Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market size was valued approximately USD 1,837 million in 2022 and the report offers an in-depth understanding of the Chronic Rhinosinusitis with Nasal Polyps, historical and forecasted epidemiology as well as the Chronic Rhinosinusitis with Nasal Polyps market trends in the 7MM.

DelveInsight’s “Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Rhinosinusitis with Nasal Polyps, historical and forecasted epidemiology as well as the Chronic Rhinosinusitis with Nasal Polyps market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Chronic Rhinosinusitis with Nasal Polyps market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Rhinosinusitis with Nasal Polyps Market Forecast

 

Some of the key facts of the Chronic Rhinosinusitis with Nasal Polyps Market Report: 

  • The Chronic Rhinosinusitis with Nasal Polyps market size was valued approximately USD 1,837 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In 2022, the collective number of prevalent cases of Chronic Rhinosinusitis (CRS) in the 7MM was identified as 69,871,809 cases, with an anticipated substantial Compound Annual Growth Rate (CAGR) projected throughout the study period spanning from 2019 to 2032.
  • In 2022, the overall identified prevalent cases of Chronic Rhinosinusitis (CRS) in the 7MM were determined to be 18,063,335. Projections indicate a notable Compound Annual Growth Rate (CAGR) for these cases during the forecast period spanning from 2023 to 2032.
  • In 2022, the 7MM recorded a total of 4,381,214 diagnosed prevalent cases of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), with an anticipated increase expected over the study period.
  • In 2022, the United States reported the highest number of diagnosed prevalent cases of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) within the 7MM, reaching 2,191,303 cases. The gender distribution reveals a male predominance in the US, with 55% of the diagnosed prevalent cases of CRSwNP being males.
  • In 2022, the European Union 4 (EU4) and the United Kingdom collectively represented 1,987,545 diagnosed prevalent cases of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). This accounted for 45% of the total diagnosed prevalent cases of CRSwNP in the 7MM.
  • Key Chronic Rhinosinusitis with Nasal Polyps Companies: AstraZeneca, Amgen, Keymed Biosciences, GlaxoSmithKline, Genentech, Inc, Novartis, Upstream Bio Inc., Regeneron Pharma, Genrix (Shanghai) Biopharmaceutical, Guangdong Hengrui Pharmaceutical, Keymed Biosciences Co.Ltd, and others
  • Key Chronic Rhinosinusitis with Nasal Polyps Therapies: FASENRA (benralizumab), Tezepelumab, CM310, GSK3511294 (depemokimab), Omalizumab, Xolair, Verekitug (UPB-101), Dupilumab SAR231893, GR1802 injection, SHR-1905 Injection, CM310, and others
  • The Chronic Rhinosinusitis with Nasal Polyps epidemiology based on gender analyzed that in 2022, out of the total diagnosed prevalent cases of CRSwNP in 7MM about 57% were male.
  • The Chronic Rhinosinusitis with Nasal Polyps market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage CRSwNP pipeline products will significantly revolutionize the Chronic Rhinosinusitis with Nasal Polyps market dynamics.

 

Chronic Rhinosinusitis with Nasal Polyps Overview

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a chronic inflammatory condition of the nasal passages and sinuses characterized by the presence of benign growths called nasal polyps. This condition involves persistent inflammation of the nasal and sinus mucosa, leading to the development of soft, non-cancerous growths within the nasal and sinus cavities.

 

Get a Free sample for the Chronic Rhinosinusitis with Nasal Polyps Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-crswnp-market

 

Chronic Rhinosinusitis with Nasal Polyps Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Chronic Rhinosinusitis with Nasal Polyps Epidemiology Segmentation:

The Chronic Rhinosinusitis with Nasal Polyps market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Chronic Rhinosinusitis with Nasal Polyps
  • Prevalent Cases of Chronic Rhinosinusitis with Nasal Polyps by severity
  • Gender-specific Prevalence of Chronic Rhinosinusitis with Nasal Polyps
  • Diagnosed Cases of Episodic and Chronic Chronic Rhinosinusitis with Nasal Polyps

 

Download the report to understand which factors are driving Chronic Rhinosinusitis with Nasal Polyps epidemiology trends @ Chronic Rhinosinusitis with Nasal Polyps Epidemiology Forecast

 

Chronic Rhinosinusitis with Nasal Polyps Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Rhinosinusitis with Nasal Polyps market or expected to get launched during the study period. The analysis covers Chronic Rhinosinusitis with Nasal Polyps market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Rhinosinusitis with Nasal Polyps Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Chronic Rhinosinusitis with Nasal Polyps Therapies and Key Companies

  • FASENRA (benralizumab): AstraZeneca
  • Tezepelumab: AstraZeneca/Amgen
  • CM310: Keymed Biosciences
  • GSK3511294 (depemokimab): GlaxoSmithKline
  • Omalizumab: Genentech, Inc
  • Xolair: Novartis
  • Verekitug (UPB-101): Upstream Bio Inc.
  • Dupilumab SAR231893: Regeneron Pharmaceuticals
  • GR1802 injection: Genrix (Shanghai) Biopharmaceutical
  • SHR-1905 Injection: Guangdong Hengrui Pharmaceutical
  • CM310: Keymed Biosciences Co.Ltd

 

Discover more about therapies set to grab major Chronic Rhinosinusitis with Nasal Polyps market share @ Chronic Rhinosinusitis with Nasal Polyps Treatment Landscape

 

Chronic Rhinosinusitis with Nasal Polyps Market Strengths

  • There is a growing focus on biologics to expand providers’ arsenal in treating patients. • The coveted approvals of NUCALA and XOLAIR in the overall existing treatment have added effectiveness intreating CRSwNP.

 

Chronic Rhinosinusitis with Nasal Polyps Market Opportunities

  • About half of the CRSwNP patients do not know the cause of their symptoms, so strategic procedures to target this patient population are expected to uplift the overall market.
  • There are opportunities for cost-effective treatment options for severe recurrent CRSwNP patients.

 

Scope of the Chronic Rhinosinusitis with Nasal Polyps Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Chronic Rhinosinusitis with Nasal Polyps Companies: AstraZeneca, Amgen, Keymed Biosciences, GlaxoSmithKline, Genentech, Inc, Novartis, Upstream Bio Inc., Regeneron Pharma, Genrix (Shanghai) Biopharmaceutical, Guangdong Hengrui Pharmaceutical, Keymed Biosciences Co.Ltd, and others
  • Key Chronic Rhinosinusitis with Nasal Polyps Therapies: FASENRA (benralizumab), Tezepelumab, CM310, GSK3511294 (depemokimab), Omalizumab, Xolair, Verekitug (UPB-101), Dupilumab SAR231893, GR1802 injection, SHR-1905 Injection, CM310, and others
  • Chronic Rhinosinusitis with Nasal Polyps Therapeutic Assessment: Chronic Rhinosinusitis with Nasal Polyps current marketed and Chronic Rhinosinusitis with Nasal Polyps emerging therapies
  • Chronic Rhinosinusitis with Nasal Polyps Market Dynamics: Chronic Rhinosinusitis with Nasal Polyps market drivers and Chronic Rhinosinusitis with Nasal Polyps market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Chronic Rhinosinusitis with Nasal Polyps Unmet Needs, KOL’s views, Analyst’s views, Chronic Rhinosinusitis with Nasal Polyps Market Access and Reimbursement 

 

To know more about Chronic Rhinosinusitis with Nasal Polyps companies working in the treatment market, visit @ Chronic Rhinosinusitis with Nasal Polyps Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Chronic Rhinosinusitis with Nasal Polyps Market Report Introduction

2. Executive Summary for Chronic Rhinosinusitis with Nasal Polyps

3. SWOT analysis of Chronic Rhinosinusitis with Nasal Polyps

4. Chronic Rhinosinusitis with Nasal Polyps Patient Share (%) Overview at a Glance

5. Chronic Rhinosinusitis with Nasal Polyps Market Overview at a Glance

6. Chronic Rhinosinusitis with Nasal Polyps Disease Background and Overview

7. Chronic Rhinosinusitis with Nasal Polyps Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Rhinosinusitis with Nasal Polyps 

9. Chronic Rhinosinusitis with Nasal Polyps Current Treatment and Medical Practices

10. Chronic Rhinosinusitis with Nasal Polyps Unmet Needs

11. Chronic Rhinosinusitis with Nasal Polyps Emerging Therapies

12. Chronic Rhinosinusitis with Nasal Polyps Market Outlook

13. Country-Wise Chronic Rhinosinusitis with Nasal Polyps Market Analysis (2019–2032)

14. Chronic Rhinosinusitis with Nasal Polyps Market Access and Reimbursement of Therapies

15. Chronic Rhinosinusitis with Nasal Polyps Market Drivers

16. Chronic Rhinosinusitis with Nasal Polyps Market Barriers

17.  Chronic Rhinosinusitis with Nasal Polyps Appendix

18. Chronic Rhinosinusitis with Nasal Polyps Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/